Antibiotics in acute exacerbations of chronic bronchitis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 4, 2010, Pages 405-417

  Sethi, Sanjay ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

Antimicrobial resistance; Chronic bronchitis; COPD; Exacerbation; Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumoniae

Indexed keywords

8 ISOPROSTANE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; COTRIMOXAZOLE; ENDOTHELIN 1; ERYTHROMYCIN; GEMIFLOXACIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; KETOLIDE; LEUKOCYTE ELASTASE; LEUKOTRIENE B4; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANTES; ROXITHROMYCIN; TELITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM DETECTION; BRONCHITIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG PENETRATION; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 77950837330     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.133     Document Type: Review

References (84)

1. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370(9589), 741-750 (2007).
2. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 346(13), 988-994 (2002).
3. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123(3), 784-791 (2003).
4. Andersson F, Borg S, Jansson SA et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96(9), 700-708 (2002).
5. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4(7), 554-564 (2007). (Pubitemid 47547851)
6. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur. Respir. J. 17(5), 928-933 (2001).
7. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117, 1345-1352 (2000).
8. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 117(5 Suppl. 2), 398S-401S (2000).
9. Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology - impact on approaches to risk stratification and therapy. Infect. Dis. Clin. North Am. 18(4), 861-882, ix (2004).
10. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359(22), 2355-2365 (2008).
11. Gump DW, Phillips CA, Forsyth BR, McIntosh FK, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am. Rev. Respir. Dis. 113, 465-473 (1976).
12. Groeneveld K, Eijk PP, van Alphen L, Jansen HM, Zanen HC. Haemophilus influenzae infections in patients with chronic obstructive pulmonary disease despite specific antibodies in serum and sputum. Am. Rev. Respir. Dis. 141, 1316-1321 (1990). (Pubitemid 20172589)
13. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch. Intern. Med. 165(8), 891-897 (2005).
14. Curran T, Coyle PV, McManus TE, Kidney J, Coulter WA. Evaluation of real-time PCR for the detection and quantification of bacteria in chronic obstructive pulmonary disease. FEMS Immunol. Med. Microbiol. 50(1), 112-118 (2007).
15. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 17(6), 1112-1119 (2001).
16. Zhu J, Qiu YS, Majumdar S et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am. J. Respir. Crit. Care Med. 164(1), 109-116 (2001).
17. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173(10), 1114-1121 (2006). (Pubitemid 43726892)
18. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 26(2), 192-203 (2005). (Pubitemid 40617296)
19. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177(5), 491-497 (2008).
20. Stockley RA. The role of proteinases in the pathogenesis of chronic bronchits. Am. J. Respir. Crit. Care Med. 150, S109-S113 (1994).
21. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58(8), 680-685 (2003).
22. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 146, 1067-1083 (1992).
23. Sethi S, Sethi R, Eschberger K et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176(4), 356-361 (2007).
24. Sethi S, Evans N, Grant BJB, Murphy TF. Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347(7), 465-471 (2002).
25. Murphy TF, Brauer AL, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177(8), 853-860 (2008).
26. Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, Lesse AJ. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J. Infect. Dis. 195(1), 81-89 (2007).
27. Sethi S, Wrona C, Grant BJB, Murphy TF. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 169, 448-453 (2004). (Pubitemid 38187115)
28. Seemungal T, Harper-Owen R, Bhowmik A et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164(9), 1618-1623 (2001).
29. Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T. Chlamydia pneumoniae infections in patients with diffuse panbronchiolitis and COPD. Chest 114(4), 969-971 (1998).
30. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 167-173 (2000).
31. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 118(6), 1557-1565 (2000). (Pubitemid 32001777)
32. Aaron SD, Angel JB, Lunau M et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163(2), 349-355 (2001).
33. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient managment of acute exacerbations of COPD. Chest 117, 1638-1645 (2000).
34. Soler N, Agusti C, Angrill J, Puig De la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62(1), 29-35 (2007). (Pubitemid 46101763)
35. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131(1), 9-19 (2007).
36. Felmingham D, White AR, Jacobs MR et al. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56(Suppl. 2), ii3-ii21 (2005).
37. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36(8), 963-970 (2003).
38. Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J. Infect. 51(5), 355-363 (2005).
39. Schito GC. Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]). J. Chemother. 16(Suppl. 6), 19-33 (2004).
40. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US years 1-4. Ann. Clin. Microbiol. Antimicrob. 7, 1 (2008).
41. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J. Clin. Microbiol. 45(2), 290-293 (2007).
42. Mera RM, Miller LA, Daniels JJ, Weil JG, White AR. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn. Microbiol. Infect. Dis. 51(3), 195-200 (2005).
43. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11(6), 851-858 (2005).
44. Hoban D, Baquero F, Reed V, Felmingham D. Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000. Int. J. Infect. Dis. 9(5), 262-273 (2005).
45. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int. J. Antimicrob. Agents 26(6), 479-485 (2005).
46. Jacobs MR, Bajaksouzian S, Windau A, et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 US Surveillance Study. Clin. Lab. Med. 24(2), 503-530 (2004).
47. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34(Suppl. 1), S4-S16 (2002).
48. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J. Antimicrob. Chemother. 54(Suppl 1), i7-i15 (2004).
49. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48(1), 56-65 (2004).
50. Saginur R. Barriers to the effective management of respiratory tract infections in the community. Infection 29(Suppl. 2), 3-10 (2001).
51. Felmingham D, Gruneberg RN. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J. Antimicrob. Chemother. 38(Suppl. A), 1-57 (1996).
52. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41(1), 118-121 (2005).
53. Querol-Ribelles JM, Molina J, Naberan K, Esteban E, Herreras A, Garcia-de-Lomas J. Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting. Int. J. Antimicrob. Agents 28(5), 472-476 (2006).
54. Weiss K, Restieri C, Gauthier R et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 33(4), 517-522 (2001).
55. Siegel RE. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place? Chest 116(2), 535-538 (1999).
56. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother. 36(6), 1171-1175 (1992).
57. Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 51(6), 339-346 (2005).
58. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125(3), 965-973 (2004).
59. File TM Jr. A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clin. Cornerstone (Suppl. 3), S21-S28 (2003).
60. File TM Jr, Hadley JA. Rational use of antibiotics to treat respiratory tract infections. Am. J. Manag. Care 8(8), 713-727 (2002).
61. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 62(3), 442-450 (2008).
62. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 63(5), 415-422 (2008).
63. Hoepelman IM, Mollers MJ, van Schie MH et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents 9(3), 141-146 (1997).
64. Roede BM, Bresser P, El Moussaoui R et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin. Microbiol. Infect. 13(3), 284-290 (2007).
65. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res. 29(4), 314-328 (2001).
66. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 23(2), 129-137 (2004).
67. Urueta-Robledo J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir. Med. 100(9), 1504-1511 (2006).
68. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl. B), 3B-32B (2003). (Pubitemid 37192994)
69. Ram FS, Rodriguez-Roisin R, Granados- Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2, CD004403 (2006).
70. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 8, 30 (2007).
71. Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 132(2), 447-455 (2007).
72. Puhan MA, Vollenweider D, Steurer J, Bossuyt PM, Ter Riet G. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med. 6, 28 (2008).
73. Sethi S. The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al. BMC Med. 6, 29 (2008).
74. Sethi S. The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Curr. Infect. Dis. Rep. 5(1), 9-15 (2003).
75. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 127(6), 2231-2236 (2005).
76. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 24(4), 639-652 (2002).
77. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125(3), 953-964 (2004).
78. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 61(4), 337-342 (2006).
79. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir. Med. 99(8), 955-965 (2005). (Pubitemid 40796538)
80. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J; for the EFEMAP Study Group. The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin. Drug Invest. 24(2), 63-72 (2004).
81. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J. 25(6), 1001-1010 (2005).
82. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 88, 61-68 (1995).
83. Dewan NA, Rafique S, Kanwar B et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 117(3), 662-671 (2000).
84. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124(2), 459-467 (2003).